AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read$JNJ

Johnson & Johnson (JNJ) Posts Q3 Results, Raises 2026 Guidance

Johnson & Johnson (JNJ) reported Q3 2026 results, with Innovative Medicine sales up 7.9% and MedTech up 2.5%, excluding currency. The company raised its full-year 2026 guidance.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Johnson & Johnson (JNJ) Posts Q3 Results, Raises 2026 Guidance — source image
Source · tradingview.com
Decision brief

The 30-second read

$JNJBullishHigh
01

Why it matters

The earnings beat and guidance raise could influence analyst forecasts and sector rotation.

02

Market read

Earnings and guidance updates are key catalysts for stock movement.

03

What to watch

Potential upcoming patent expirations or regulatory risks not discussed.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Johnson & Johnson is a diversified healthcare company with segments in Innovative Medicine and MedTech.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson posted Q3 2026 results and raised its full-year 2026 guidance.

Expected impact

upward pressure as investors price in higher earnings expectations

Evidence & confidence

Guidance upgrades historically lead to price appreciation for large-cap pharma stocks.

Market effects

Sector

May boost sentiment for the broader healthcare and pharma sector.

Regional

Positive for U.S. large-cap equities.

Global

Limited to investors tracking global pharma earnings.

Counterpoint

What could challenge this read

If guidance raise is already priced in, the stock may face a short-term pullback.

Key entities

  • company
    Johnson & Johnson

    US-listed healthcare conglomerate.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 13
$JNJHighAI 8/10

Tremfya rescues J&J’s immunology sales to fuel strong Q3

Johnson & Johnson reported Q3 sales of $25.4bn, beating estimates. Tremfya's sales surged 68.3% to $2.4bn, driving a 7.9% increase in the pharma segment. Overall immunology sales grew 1.3%, offset by declines in Stelara, Remicade, and Simponi. J&J raised its 2026 sales and EPS guidance, despite lower Q3 EPS due to acquisitions and legal settlements. Medtech sales grew 2.5%, led by Shockwave's 16.8% increase.

finance.yahoo.com2 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson raises 2026 guidance as quarterly sales climb

Johnson & Johnson (JNJ) raised its 2026 sales and earnings forecasts after Q3 sales grew 6%. Full-year sales midpoint increased to $101.2B, and adjusted EPS midpoint rose by $0.06 to $11.10. Q3 sales reached $25.4B, with adjusted EPS at $2.59. Growth was driven by Innovative Medicine and MedTech divisions, while Stelara sales declined. Shares fell over 5% on the news.

finance.yahoo.com2 min
OCT 13
$JNJHighAI 9/10

J&J Q3 2026 slides: $25.4B revenue, OTTAVA FDA win, margins pressured

Johnson & Johnson (JNJ) reported Q3 2026 revenue of $25.4B, up 5.9%, but shares fell 4.36% due to margin pressure. Adjusted EPS declined 7.5% YoY to $2.59. U.S. sales grew 9.1%, while international sales rose 1.8%. Innovative Medicine saw 7.9% growth, but MedTech lagged with 2.5% growth. The FDA approved the OTTAVA Robotic System, a new surgical robotics category. The company raised its full-year 2026 guidance.

investing.com2 min
OCT 13
$JNJHighAI 8/10

Johnson & Johnson Q3 2026 earnings: CEO and CFO prepared remarks

Johnson & Johnson reported Q3 2026 operational sales growth of 6%, exceeding analyst consensus. The company highlighted strong performance in Oncology, Immunology, and Neuroscience, with several key products driving growth. CEO Joaquin Duato expressed confidence in meeting annual guidance and exceeding $100 billion in revenue for the first time. MedTech segment grew 2.5%, with notable advancements in Cardiovascular and Surgery.

marketscreener.com2 min